2,527 followers
@liammannix @AndrewMoorepain Looks like a fairly small trial (n=134). Interesting they used capsules and not nabiximols buccal spray, which is a cannabis medicine registered to treat MS spasticity in Europe and Australia. Other RCTs in similar cohorts have